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ABSTRACT 
Hyperlipidemia is produced due to abnormal elevated level of lipids in the blood and is a major risk factor for many heart diseases such as 
atherosclerosis and stroke.  Lipids have been implicated in the development of atherosclerosis in humans. In hyperlipidemia there are 
increased levels of both LDL and triglycerides. Treatment of hyperlipidemia with statins has become an integral part of management of vascular 
diseases. Statins are the first line therapy for lowering lipid levels. Among statins atorvastatin is the most effective and currently available 
antihyperlipidemic drug. An enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase play an important for endogenous 
cholesterol synthesis. Atorvastatin is HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitor which significantly reduces the lipid 
levels (low-density lipoprotein, triglycerides, very low-density lipoprotein) and also increases the HDL (high-density lipoprotein) levels. 
Various analytical methods such as reverse phase high-performance liquid chromatography (RP-HPLC), high performance thin layer 
chromatography (HPTLC), thin layer chromatography (TLC), ultra-performance liquid chromatography (UPLC), liquid chromatography tendam 
mass spectroscopy, near infrared spectroscopy, capillary electrophoresis (CE), spectrophotometric methods for determination of atorvastatin 
as single and in combination with other drugs have been reported.  In this review an attempt has been made to covers all the recent analytical 
methods which has been used for analysis of atorvastatin. 
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INTRODUCTION 
Atorvastatin is chemically (3R,5R)-7-[2-(4-Fluorophenyl)-3-
phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-
dihydroxyheptanoic acid (Figure1)1,2. Atorvastatin is 
antilipidemic agent and it is a member of the drug class 
known as statins.3 It is an inhibitor of 3-hydroxy-3-
methylglutaryl-coenzymeA (HMG-CoA) reductase enzyme 
that participates in the endogenous cholesterol synthesis.4 
The drug is odorless white crystalline powder and 
practically insoluble in water, soluble in methanol, slightly 
soluble in methylene chloride. 5 Atorvastatin is more potent 
and appears to have the highest LDL-CH lowering efficacy at 
maximal daily dose of 80 mg. At this dose a greater 
reduction in TGs is noted if the same was raised at baseline. 
Atorvastatin has a much longer plasma half-life of 18-24 hr. 
than other statins and has additional antioxidant property.6 
The ortho and para hydroxylated products are the main 
metabolite of Atorvastatin.7 The most common side effects of 
Atorvastatin are runny nose, sneezing and coughing and gas. 
Serious side effects include muscles problems, liver 
problems, loss of appetite; upper stomach pain.8Atorvastatin 
is contraindicated during pregnancy and in nursing mothers. 
It should not be used in children or teenagers.9    
Ketoconazole, cyclosporine, erythromycin: enhanced effect 
and risk of myopathy with statins; niacin, gemfibrozil 
enhance reduction in LDL levels but increase risk of 
myopathy with statins.10      
 Dosage                        
Adults: Dose: 10-40 mg/ day (max. 80 mg).11   
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Combinations of Atorvastatin12 ,13: 
1. Atorvastatin + Losartan 
2. Atorvastatin + Irbesartan and other angiotensin 
receptor blocker 
3. Atorvastatin + Ezetimibe 
4. Atorvastatin + Ramipril 
5. Atorvastatin + Glimepiride and another Antidiabetic 
agent 
6. Atorvastatin + Fenofibrate 
7. Atorvastatin + Amlodipine 
8. Atorvastatin + B Group vitamin 
9. Atorvastatin +Nicotinic Acid 
10. Atorvastatin + Aspirin, Clopidogrel 
11. Atorvastatin + Atenolol 
12. Atorvastatin+ Hydrochlorothiazide    
ANALYTICAL METHODS 
For the estimation of atorvastatin in pharmaceutical dosage 
form and in human plasma various analytical methods such 
as HPLC, HPTLC, TLC, Spectrophotometric methods, 
Capillary electrophoresis, UPLC, LC/MS methods have been 
reported, among these methods HPLC is most important 
analytical method which have been widely used for the 
quantitative analysis of atorvastatin. In this review an 
attempt has been made to compiled all the analytical 
methods which have been recently used for the analysis of 
atorvastatin.  
1. HPLC Chromatographic methods: 
Several high-pressure liquid chromatographic (HPLC) 
methods have been reported for determination of 
atorvastatin in single and combination with others drug. 
HPLC methods are widely used chromatographic method for 
analysis of atorvastatin in plasma and pharmaceutical 
dosage form.   RP-HPLC method was developed by 
Bangaruthalli et al (2019) for simultaneous estimation of 
telmisartan and atorvastatin calcium. The separation was 
obtained on ODS C18 column with flow rate 1.0ml/min.  
Mobile Phase consists of methanol: acetonitrile: buffer in 
ratio of 35:25:40 and the detection was carried out at 
235nm.The instrument used was SHIMADZU HPLC auto 
sampler. The retention time of atorvastatin calcium and 
telmisartan was found to be 2.350 and 3.490 minutes 
respectively. The correlation coefficient (r2) was found to be 
0.997 and 0.999 for telmisartan and atorvastatin calcium 
respectively and the % mean recovery was found to be 
100.943% and 100.576% for telmisartan and atorvastatin 
calcium respectively. 14   In another study Chaudhari et al. 
(2018) worked on RP-HPLC method development and 
validation for simultaneous estimation of atorvastatin, 
aspirin, ramipril and metaprolol succinate in tablet dosage 
form. All the drugs were separated on a (250 cm.×4.6 mm,) 
C18 column with a 5µm particle size. The mobile phase, 
which optimized through an experimental design, was a 
90:10 (v/v) mixture of phosphate buffer (pH 4) an 
acetonitrile, pumped at a flow rate of 1ml/min. UV detection 
was performed at 210 nm. The retention time of 
atorvastatin, aspirin, ramipril and metoprolol succinate was 
found to be 8.013 min, 4.497 min, 7.240 min and 3.403 min 
respectively. The method was validated with concentration 
ranges of 3-9µg/ml for atorvastatin, 22.5 9µg/ml-
67.59µg/ml for aspirin, and 1.54.59µg/ml for ramipril and 
15-45µg/ml for metoprolol succinate. The LOD values were 
0.3489µg/ml, 2.6739µg/ml, 0.2369µg/ml and 1.6279µg/ml 
while the LOQ values were 1.056µg/ml, 8.100µg/ml, 0.716 
µg/ml and 4.931 µg/ml for atorvastatin, aspirin, and 
ramipril and metoprolol succinate.15 In 2018 Pratiksha et al.  
reported stability indicating RP-HPLC method for estimation 
of atorvastatin and clopidogrel in pharmaceutical dosage 
form. The chromatographic separation was achieved on a 
C18 column using a mixture of phosphate buffer (pH= 3.0): 
acetonitrile (40:60) as a mobile phase and UV detection of 
analyte was carried out at 242nm. Atorvastatin and 
clopidogrel eluted at retention time 6.90 and 10.05 
respectively. Current method was validated with respect to 
precision, accuracy, linearity, robustness according to ICH 
guidelines. Atorvastatin, clopidogrel and their combination 
drug product was subjected to stress conditions (acid, base, 
oxidation, thermal, humidity and photolysis). Major 
degradation was found under thermal and humidity stress 
conditions while only a minor degradation was observed 
during photolysis. 16 A fast and validated RP-HPLC method 
was carried out by Hassan et al (2018) for simultaneous 
determination of simvastatin, atorvastatin, telmisartan and 
irbesartan in bulk drugs and tablet formulations. In this 
study the chromatographic separation was accomplished by 
using symmetry C18 column (75 mm × 4.6 mm; 3.5 µm) with 
a mobile phase consisting of ammonium acetate buffer (10 
mM; pH 4.0) and acetonitrile in a ratio 40:60 v/v. Flow rate 
was maintained at 1 ml/min up to 3.5 min, and then 
suddenly changed to 2ml/min till the end of the run 
(7.5min). The data was acquired using ultraviolet detector 
monitored at 220 nm. The method was validated for 
linearity, precision, accuracy and speciﬁcity. The developed 
method has shown excellent linearity (r2 > 0.999) over the 
concentration range of 1–16 µg/ml. The limits of detection 
(LODs) and limits of quantiﬁcation (LOQ) were in the range 
of 0.189–0.190 and 0.603–0.630 µg/ml, respectively. 17. 
Tomlesh et al. (2018) worked on development and method 
validation of atorvastatin calcium and telmisartan in tablet 
dosage form by RP-HPLC method. The HPLC separation was 
achieved on Chemsil C18 column (150 mm x 4.6 mm id, 5 μ 
particle size) with isocratic condition at ambient 
temperature using mobile phase as a buffer (0.02 M 
ammonium acetate buffer pH 4.0 by glacial acetic acid): 
acetonitrile: tetrahydrofuran in the ratio (400:400:14 
v/v/v). The analysis was performed at flow rate 1.5 ml/min. 
Quantification was achieved with UV detection at 246 nm. 
Retention time of atorvastatin calcium and telmisartan were 
found to be 5.70 ± 0.20 minute and 6.72 ± 0.20 minute 
respectively. The linearity was studied in the concentration 
range 10-60 μg/ml and 402-40 μg/ml for atorvastatin 
calcium and telmisartan respectively.18  Determination of 
atorvastatin in tablet by RP-HPLC was carried out by 
Yugatama et al. (2017) in this study the experiment was 
performed on Cosmosil C18 (150 cm x 4.6 mm, 5µm) column 
as the stationary reverse phase chromatography, a mixture 
of methanol-water at pH 3 (80:20 v/v) used as the mobile 
phase, flow rate was maintained 1 ml/min and UV detection 
was carried out at wavelength of 245 nm. LOD and LOQ were 
found 0.2 and 0.7 ng/ml and the developed method showed 
good linearity in the concentration range 20 - 120 ng/ml. 19 
In another study Porwal et al. (2017) reported validated 
HPLC-UV method for simultaneous determination of 
metformin, amlodipine, glibenclamide and atorvastatin in 
human plasma and application to protein binding studies. 
Optimum separation conditions were obtained with Water’s 
Novapack Phenyl (150 mm×4.6 mm, i.d., 5.0 μm) column 
with mobile phase consisting of 0.1% Phosphoric acid (pH 
3.0) and acetonitrile (ACN) in gradient mode with column 
oven temperature maintained at 30°C and elution monitored 
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by a UV detector at 227 nm. Protein precipitation was 
employed to extract the selected analyte form human 
plasma. The recoveries were found more than 90% for all 
analytes in cold aqueous 10% trichloroacetic acid (TCA) and 
acetonitrile. The accuracy of samples for six replicate 
measurements at LLOQ (Lower limit of quantification) level 
was within limit.20 HPLC and capillary electrophoresis (CE) 
study for simultaneous determination of amlodipine and 
atorvastatin in the presence of their acidic degradation 
products in tablets was carried out by Hassan et al. (2016). 
In this proposed work two methods were developed for 
separation and quantitation of amlodipine (AML) and 
atorvastatin (ATV) in the presence of their acidic 
degradation products. The first method was a simple 
isocratic RP-HPLC method while the second was capillary 
electrophoresis (CE).  For HPLC separation used Agilent 
zorbax® ODS column (5 µm, 4.6 x 250 mm) and flow rate 
was maintained 1.0 ml/ min. UV detection were performed 
at 254.0 nm. An Agilent 7100 CE system, with a diode array 
detector (Agilent Technologies) was controlled by 
chemstation software. The mobile phase was prepared by 
mixing acetonitrile: methanol: phosphate buffer pH = 3.0 
(45:30:25, V/V/V); pH was adjusted to 2.5 ± 0.1 with 
orthophosphoric acid. CE separation was carried out at 18 ± 
2 °C using a voltage of 15 kV (positive polarity) and 
detection was carried out at 200 nm. Peak purity was 
assessed using DAD (diode array detector). Bare fused silica 
capillaries (Agilent Technologies) of 50 µm id, 325 µm od, 
with a total/effective length of 48.5/40.0 cm was used 
during analysis. Preconditioning of the capillary before each 
run was carried out by flushing with 0.1 mol/l NaOH, MilliQ 
water and finally with a background electrolyte (BGE) for 3 
min each. Post-conditioning was carried out by flushing with 
MilliQ water for 5 min. Samples were injected 
hydrodynamically at 5 kPa for 5 s and 50 mmol/l borate 
buffer at pH 8.0 was used as the BGE. TLC plates 20 x 20 cm 
(Sigma-Aldrich, Germany) were coated with a 0.2-mm silica 
gel 60 F254 layer. The sample was applied to the plates 
using micro-droppers and a UV lamp at 254 nm was used for 
visualization of the spots. The linearity of the proposed 
methods was established over the ranges 1–50 μg m/l for 
AML and ATV in the HPLC method and in the range of 3–50 
and 4–50 μg/ml AML and ATV, respectively, in the CE 
method. 21 Sangshetti et al (2016) worked on development 
and validation of RP-HPLC method for determination of 
atorvastatin calcium and nicotinic acid in combined tablet 
dosage form. The analysis has been performed by using 
Agilent ZORBAX SB-C18 (150×4.6 mm, 3.5um) and mobile 
phase containing acetonitrile: distilled water (85:15) at pH 
4.5 (adjusted with phosphoric acid). The detection was 
carried out at 261 nm with a ﬂow rate of 1.0 ml/min. The 
retention times of atorvastatin calcium and nicotinic acid 
were found 6.092 and 3.125 min, respectively. The linearity 
for atorvastatin calcium and nicotinic acid were in the range 
of 2–12 and 10–80 μg/ml respectively. The recoveries of 
atorvastatin calcium and nicotinic acid were found to be in 
the range of 99.031% and 99.744% respectively.22   In 2016 
Cansel et al. conducted development of a suitable dissolution 
method for the combined tablet formulation of atorvastatin 
and ezetimibe by RP-LC method. In this proposed method, 
the effects of pH and surfactant on the dissolution of poorly 
water-soluble combined drug therapy with a different pKa 
values in an in vitro environment was investigated. The 
optimized test conditions achieved under sink conditions 
with USP apparatus 2 at a paddle rotation speed of 75 rpm 
and 900 ml in 0.01 M acetate buffer (pH= 6.8) containing 
0.45% SDS as a dissolution medium. Quantification of 
dissolution samples were analyzed with a new fully 
validated RP-LC method with UV detection at 242 nm.23 
Bkhaitan et al. (2015) carried out stability‐indicating 
HPLC‐DAD method for simultaneous determination of 
atorvastatin, irbesartan, and amlodipine in bulk and 
pharmaceutical preparations. Separation was executed on a 
Waters XBrigde C18 column (5 µm, 25 × 0.46 cm) using a 
gradient mobile phase system consisting of acetonitrile and 
orthophosphoric acid buffer (pH 2.2) at a flow rate of 
1 ml/min with UV detection at 240 nm. The drugs were 
subjected to acidic and basic hydrolysis, oxidation, exposure 
to UV light, and exposure to temperature (dry heat) to apply 
stress conditions. Linearity of the method was evaluated in 
the range 5–30 µg/ml for each drug with correlation 
coefficient values (r 2) of 0.9982, 0.9973, and 0.9986 for 
atorvastatin, irbesartan, and amlodipine, respectively. The 
limits of detection were 0.05, 0.06, and 0.08 µg/ml for the 
three compounds, respectively. 24. In 2014 Kumar et al. 
carried out new validated RP-HPLC analytical method for 
simultaneous estimation of atorvastatin and ezetimibe in 
bulk samples as well in tablet dosage forms by using PDA 
detector The chromatographic separation was performed on 
an X Terra C8 (4.6 x 250 mm; 5 µm), with phosphate buffer 
[pH 3.5] and acetonitrile in the ratio of 40:60 (v/v) as mobile 
phase. The detection was carried out at 240 nm. The 
accuracy was found to be 99.59% and 98.98% for 
atorvastatin and ezetimibe respectively. The linearity was 5-
25 µg/ml for both the drugs. The intra-day RSD was 0.57% 
and inter-day RSD was 0.13% for atorvastatin calcium and 
intra-day RSD was 0.56% and inter-day RSD was 0.09% for 
ezetimibe.25 In another study Kurakula et al. (2014) carried 
out development and validation of a RP-HPLC method for 
assay of atorvastatin and its application in dissolution 
studies on thermosensitive hydrogel-based nanocrystals. 
Chromatographic identification was achieved on C18 (5 µm) 
column using acetonitrile and 0.025 M potassium 
dihydrogen ortho-phosphate buffer pH 5 (45:55 v/v) as 
mobile phase, at a ﬂow rate of 1.5 ml/min. Detection was 
carried out with photo diode array detector (PDA) at 246 
nm. The developed HPLC method was validated according to 
International Conference on Harmonisation (ICH) Q2(R1) 
guidelines and applied to dissolution studies on atorvastatin 
thermosensitive hydrogel-based nanocrystal formulation, 
using Lipitor® as standard.  The retention time of 
atorvastatin was 4.5 min and drug response were linear in 
the range of 0.1 - 0.5 µg/ml with a correlation coefficient of 
0.9995. Precision was determined to be between 0.16 - 0.61 
percent relative standard deviation (% RSD) for the 
analysed samples. The limit of detection and of 
quantification was 35.6 and 71.2 ng/ml. The assay of 
atorvastatin nanocrystal and Lipitor® gave 99.37 and 99.12 
% recovery, respectively. Dissolution studies showed 
atorvastatin release of 40 and 65 % at 40 min from 
thermosensitive hydrogel nanocrystal formulation and 
Lipitor®, respectively indicating sustained release.26 Oliveira 
et al. (2013) studied degradation kinetics of atorvastatin 
under stress conditions and chemical analysis by HPLC. The 
chromatographic separation was achieved on C18 column 
(ODS, 250 × 4 mm, 5 μm, SunFire) with mobile phase: 
acetonitrile/phosphoric acid 0.1% v/v (65:35). The flow rate 
was maintained 1.5 ml/min during study. The injection 
volume was 10 μl and detection was carried out with UV-
DAD at λ max 238 nm at 303 K. ATV has been found to 
degraded under acid and basic conditions, including a first 
order kinetic degradation under acid conditions, as 
compared to a zero-order kinetic degradation under basic 
conditions, which tends to be less stable when studied 
within acid mediums. The linear correlation coefficient (r2) 
was found greater than 0.99 in concentration range of 14 to 
26 μg/ml. A detection limit was found 0.45 μg/ml and a 
quantification limit was found 1.36 μg/ml.27 Simultaneous 
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estimation and validation of atorvastatin calcium (AST) and 
aspirin (ASP) in combined capsule dosage form by RP HPLC 
was carried out by Suma et al. (2012). The chromatographic 
separation was achieved on a 5 – micron C 18 column (250 x 
4.6mm) using a mobile phase consisting of a mixture of 
acetonitrile: ammonium acetate buffer 0.02M (68:32) pH 4.5. 
The flow rate was maintained at 0.8 ml / min. The detection 
of the constituents was done using UV detector at 245 nm 
for AST and ASP. The retention time of AST and ASP were 
found be 4.5915 ± 0.0031min and 3.282 ±0.0024 min 
respectively. 28 In 2012 Bhinge et al. reported a new 
approach to the RP-HPLC method for simultaneous 
estimation of atorvastatin calcium and fenofibrate in 
pharmaceutical dosage forms. Atorvastatin calcium, 
fenofibrate and diclofenac (internal standard) were well 
separated using a reversed phase column and mobile phase 
consisting of acetonitrile: potassium di hydrogen phosphate 
(50 mm) (72:28 v/v) (pH 4.1). The mobile phase was 
pumped at 1.0 ml/min flow rate and atorvastatin calcium 
and fenofibrate were detected by uv-vis detection at 260 nm. 
The retention time for atorvastatin calcium, internal 
standard and fenofibrate were 4.34, 5.35 and 12.05 min, 
respectively. The LOD and LOQ was found to be 1.95 and 
4.80 µg/ml for atorvastatin calcium whereas for fenofibrate 
it was found to be 1.73 and 3.98 µg/ml in mobile phase.29 
Talluri et al. (2012) worked on synchronized separation of 
atorvastatin—an antihyperlipidemic drug with 
antihypertensive, antidiabetic, antithrombotic drugs by RP-
LC for determination in combined formulations. The 
chromatographic separation was carried out by gradient 
elution mode with acetonitrile as organic modiﬁer and 0.1% 
triethylamine acetate (TEAA) buffer pH 5 at a ﬂow rate of 1 
ml/min and a diode array detector at wavelength 230 nm 
was employed for detection of the analytes. Calibration 
curves were linear in the range of 5–150 mg/ml for all the 
drugs with correlation coefﬁcients of determination (r2 
values) 0.999. Limits of detection (LODs) and Limits of 
quantiﬁcation (LOQs) ranged from 0.1 to 0.27 mg/ml and 0.3 
to 0.89 mg/ml respectively. Intra-day and inter-day 
precision were studied at three concentration levels (20, 60 
and 100 mg/ml). The intra-day and inter-day RSD for all 
compounds was less than 2.0%. The accuracy for all 
compounds was found to be between 98% and 102%.30 
Nagaraju et al. (2011) developed and validated RP-HPLC 
method for the estimation of atorvastatin calcium in bulk 
and pharmaceutical formulations. The separation was 
achieved on Phenomenex C18 (250 × 4.6 mm, 5µ) column 
using a mobile phase containing of acetonitrile: ortho-
phosphoric acid (0.1%): tetrahydrofuran (48:0.04:52). The 
eluent was monitored at 244 nm. The results have been 
validated statistically and recovery studies confirmed the 
accuracy of proposed method.31 Simultaneous estimation of 
atorvastatin calcium and fenofibrate in tablet dosage form 
was carried out by Hirave et al. (2010) by RP-HPLC. The best 
separation was achieved on HiQ sil C8 (4.6x250mm) column. 
Detection of the drugs was carried out at 260 nm  by using a 
mobile phase having composition methanol: water pH 3.2 
(90:10 v/v) at a flow rate of 1 ml/min. 32 In 2010 Jena et al. 
reported an analytical method for the simultaneous 
determination of atorvastatin calcium and amlodipine 
besylate in tablet dosage by RP-HPLC. The chromatographic 
resolution of drugs was achieved in mobile phase having 
composition of a phosphate buffer (1 ml ortho phosphoric 
acid in 1000 ml of water) acetonitrile and methanol in the 
ratio 53:43:4 v/v by using Grace Smart RP C18 column (250 
x 4.6, 5µm). The samples were eluted at 1 ml/min and UV 
detection was carried out at 246 nm using photo dine array 
detector.33 Kumar et al. (2010) proposed a new RP-HPLC 
method for simultaneous estimation of atorvastatin calcium 
and telmisartan in tablet dosage form. Chromatographic 
separation of selected drugs was achieved on (Waters 
symmetry C18, 250mm x 4.6mm, 5µ) column. Composition 
of mobile phase was maintaining ammonium acetate (0.02M, 
pH 4.0 adjusted with glacial acetic acid) and acetonitrile in 
ratio 40:60 v/v.  The detection wavelength was 254 nm and 
flow rate were maintained 1.0 ml/min.34 Shetty et al. (2010) 
worked on quantitative application to a polypill by the 
development of stability indicating LC method for the 
simultaneous estimation of aspirin, atorvastatin, atenolol 
and losartan potassium. Efficient chromatographic 
separation was achieved on a C18 stationary phase with 
simple mobile phase combination of buffer and acetonitrile: 
buffer consists of 0.1% orthophosphoric acid (pH 2.9), 
delivered in a gradient mode and quantitation was carried 
out using ultraviolet detection at 230 nm with a flow rate of 
1.0 ml/min. The retention times of atenolol, aspirin, losartan 
potassium, and atorvastatin were 3.3, 7.6, 10.7 and 12.9 min 
respectively. The combination drug product was exposed to 
thermal, acid/base hydrolytic, humidity and oxidative stress 
conditions, and the stressed samples were analysed by 
proposed method. The method was validated with respect to 
linearity; the method was linear in the range of 37.5 to 150.0 
µg/ml for ASP (aspirin), 5.0 to 20.0 µg/ml for ATV 
(atorvastatin) and 25.0 to 100.0 µg/ml for ATL (atenolol) 
and LST (losartan potassium). Acceptable precision and 
accuracy were obtained for concentrations over the 
standard curve ranges. The validated method was 
successfully applied to the analysis of star pill tablets 
constituting all the four drugs; the percentage recoveries 
obtained were 99.60% for ASP, 99.30% for ATV, 99.41% for 
ATL and 99.62% for LST.35 Stability indicating RP-HPLC 
method for simultaneous determination of atorvastatin 
(ATR) and nicotinic Acid (NTA) was proposed by Gupta et al. 
(2009). The proposed RP-HPLC method utilizes a 
Phenomenex® C18, 5µm, 250mm X 4.6mm i.d. column, at 
ambient temperature, optimum mobile phase consisted of 
acetonitrile and 50mM potassium dihydrogen phosphate 
buffer (68:32, v/v), pH adjusted to 4.5±0.1 with phosphoric 
acid solution, effluent flow rate monitored at 0.8 ml/min, 
and UV detection at 247 nm. The combination drug product 
was exposed to thermal, acid/base hydrolytic, humidity and 
oxidative stress conditions, and the stressed samples were 
analysed by proposed method. The described method was 
linear over the range of 2-10 µg/ml and 20-100 µg/ml for 
ATR and NTA, respectively. The mean recoveries were 
100.99 and 102.65% for ATR and NTA, respectively. The 
limit of detection for ATR and NTA was found to be 0.16 and 
0.12 µg/ml, respectively.36 Zaheer et al. (2008) worked on 
stability-indicating high-performance liquid 
chromatographic determination of atorvastatin calcium in 
pharmaceutical dosage form. The chromatographic 
conditions comprised of a reversed-phase C18 column (250 
x 4.6 mm), 5 µ with a mobile phase consisting of a mixture of 
methanol: acetonitrile: phosphate buffer solution in the ratio 
(45:45:10).  Flow rate was 1 ml/ min. Detection was carried 
out at 246 nm. The retention time of atorvastatin was 6.98 
min. Atorvastatin calcium was subjected to acid and alkali 
hydrolysis, oxidation, photochemical degradation and 
thermal degradation. The linear regression analysis data for 
the calibration plots showed good linear relationship in the 
concentration range 52.20 to 156.60 µg/ml. The value of 
correlation coefficient, slope and intercept were, 0.9999, 
36.02 and 26.45, respectively. The drug showed degradation 
under acidic, basic, photochemical and thermal degradation 
conditions. All the peaks of degraded product were resolved 
from the active pharmaceutical ingredient with significantly 
different retention time. Another RP-HPLC method for 
simultaneous determination of atorvastatin calcium and 
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ezetimibe in pharmaceutical formulations was reported by 
Qutab et al. (2007), best separation of selected drugs was 
achieved on a 250 x 4.6 mm, 5µ Hypersil phenyl-2 column. 
Eluent was monitored at 242 nm using a solvent system of 
0.1 M ammonium acetate (pH 6.5) and acetonitrile in the 
ratio of 28:72 (v/v). 38 Shah et al. (2007) developed and 
reported a RP-HPLC method for determination of 
atorvastatin calcium and nicotinic acid in combined tablet 
dosage form. Chromatographic separation was achieved on 
Phenomenex Luna C18, 5 mm column having 250 x 4.6mm 
i.d. Isocratic separation was achieved with mobile phase 
containing 0.02 M potassium dihydrogen phosphate: 
methanol: acetonitrile (20:40:40, pH 4). Samples were 
eluted with flow rate 1.0 ml/min and effluents were 
monitored at 240 nm. 39 Shah et al. (2007) worked on 
stability indicating RP-HPLC estimation of atorvastatin 
calcium and amlodipine besylate in pharmaceutical 
formulations. Best separation was found on Phenomenex 
Gemini C18 (250 × 4.6 mm i.d., 5μm) column with isocratic 
mode. The mobile phase consisted of 0.02 M potassium 
dihydrogen phosphate: MeOH (20: 80, pH 4.0). The flow rate 
was maintained 1.0 ml/min and drugs were monitored at 
240 nm.40 In 2007 Mohammadi et al. carried out stability-
indicating high-performance liquid chromatographic (HPLC) 
assay for the simultaneous determination of atorvastatin 
(AT) and amlodipine (AM) in commercial tablets. The 
separation was achieved on a Perfectsil Target ODS-3 (250 × 
4.6 mm i.d., 5 μm) column using a mobile phase consisting of 
acetonitrile-0.025 M NaH2PO4 buffer (55:45, v/v, pH 4.5), 
flow rate was maintained 1 ml/min and UV detection was 
carried out at 237 nm. The drugs were subjected to 
oxidation, hydrolysis, photolysis and heat to apply stress 
conditions. Degradation products produced as a result of 
stress studies did not interfere with the detection of AT and 
AM and the assay can thus be considered stability-indicating. 
41 Alla (2007) has reported a stability-Indicating LC method 
for the simultaneous determination of metoprolol (ME), 
atorvastatin (AT) and ramipril (RA) in combined 
pharmaceutical dosage form. A chromatographic separation 
of the three drugs was achieved with a Hypersil C8, 15-cm 
analytical column using buffer-acetonitrile (55:45 v/v). The 
buffer used in mobile phase contains 0.02 M sodium 
perchlorate in double distilled water.  The flow rate was 
maintained 1.0 ml/min and detection was carried out at 
wavelength 210 nm for ME, AT and RA using as ultra violet 
detector.  Methanol was used as diluent. The resolution 
among ME, AT and RA were found to be more than 2.0. 
Theoretical plates for ME, AT and RA were >2500.42 
Stability-indicating reversed-phase liquid chromatographic 
methods for simultaneous determination of atorvastatin and 
ezetimibe from their combination drug products was carried 
out by Chaudhari et al. (2007). Separation of atorvastatin 
(ATV) and ezetimibe (EZE) was obtained on Li Chrospher 
100 C18, 5-micron, 250 cm x 4.0 mm id column at ambient 
temperature with mobile phase consists of acetonitrile-
water-methanol (45+ 40 + 15, v/v/v) having pH 4.0 ± 0.1. 
The flow rate was maintained 1.0 ml/min and   UV detection 
was carried out at 250 nm. ATV, EZE, and their combination 
drug product were exposed to thermal, photolytic, 
hydrolytic, and oxidative stress conditions, and the stressed 
samples were analysed by the proposed method. The 
response was found linear over the concentration range of 
1-80 μg/ml for ATV and EZE. The mean recoveries were 
found 99.27 and 98.5% for ATV and EZE, respectively.43 Raja 
et al. (2006) have developed a RP-HPLC method for the 
simultaneous determination of atorvastatin and amlodipine 
in tablet dosage form. The mobile phase used was a mixture 
of acetonitrile and 0.03 M phosphate buffer (55:45 v/v, pH 
2.9). The detection of atorvastatin and amlodipine was 
carried out on dual γ absorbance detector at 240 nm and 
362 nm, respectively.  44. Stanisz et al. (2006) carried out 
validation of HPLC method for determination of atorvastatin 
in tablets and for monitoring stability in solid phase. 
Separation of atorvastatin was successfully achieved on a C-
18 column utilizing water and acetonitrile at the volumetric 
ratio of 48:52, adjusted to pH 2.0 with 80% ortho-
phosphoric acid. The detection wavelength was 245 nm. The 
method was validated and the response was found to be 
linear in the drug concentration range of 0.04 mg/ml and 0.4 
mg/ml. The mean values ± RSD of the slope and the 
correlation coefficient were 8.192 ± 0.260 and 0.999, 
respectively. The RSD values for intra- and inter day 
precision were < 1.00% and 0.90%, respectively. The 
degradation kinetic of atorvastatin at 363 K in a relative 
humidity of 76.4% was observed to be autocatalytic first 
order reaction. The kinetic parameters were as follows: k 
(where k represents the velocity constant; s-1) = (1.42 ± 
0.19) 10-6; t0.5 (where t0.5 represents the time needed for a 
50% decay of atorvastatin; days) = 32.82 ± 0.9; t0.1(where 
t0.1 represents the time needed for a 10% decay of 
atorvastatin; days) = 13.86 ± 0.8.45 Pasha et al. (2006) 
carried out analysis of five HMG-CoA reductase inhibitors- 
atorvastatin, lovastatin, pravastatin, rosuvastatin and 
simvastatin: pharmacological, pharmacokinetic and 
analytical overview and development of a new method for 
use in pharmaceutical formulations analysis and in vitro 
metabolism studies. For separation of drugs ternary 
gradient elution at a flow rate of 1 ml/min was employed on 
an Intertisl ODS 3V column (4.6 x 250 mm, 5 microm) at 
ambient temperature. The mobile phase consisted of 0.01 m 
ammonium acetate (pH 5.0), acetonitrile and methanol. 
Theophylline was used as an internal standard (IS). The 
HMG-CoA reductase inhibitors and their metabolites were 
monitored at a wavelength of 237 nm. Drugs were found to 
be 89.6-105.6% of their label's claim in the pharmaceutical 
formulations. For in vitro metabolism studies the reaction 
mixtures were extracted with simple liquid-liquid extraction 
using ethyl acetate. Baseline separation of statins and their 
metabolites along with IS free from endogenous 
interferences was achieved. Nominal retention times of IS, 
atorvastatin, lovastatin, pravastatin, rosuvastatin and 
simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5 and 35.5 min, 
respectively.46  Determination of atorvastatin in human 
serum by reversed-phase high performance liquid 
chromatography with UV detection was carried out by 
Bahrami et al. (2005). Chromatographic separation was 
accomplished using C18 analytical column with a mobile 
phase consisting of sodium phosphate buffer (0.05 M, pH 
4.0) and methanol (33:67, v/v).  Atorvastatin and the 
internal standard were detected by UV absorbance at 247 
nm. The average recoveries of the drug and internal 
standard were 95 and 80 %, respectively. The analytical 
performance was studied and the method was applied in a 
randomized cross-over bioequivalence study of two 
different atorvastatin preparations in 12 healthy 
volunteers.47   In 2004 Manoj et al. reported RP HPLC method 
for simultaneous estimation of atorvastatin and aspirin in 
capsule formulation. The maximum resolution was achieved 
by mobile phase acetonitrile: 0.05 M potassium dihydrogen 
phosphate buffer: methanol in the ratio (50:30:20, v/v/v) at 
pH 3.0.  This mixture was found to be appropriate allowing 
good separation of both the components at a flow rate of 1.5 
ml/min and detection wavelength 240 nm.  In these 
condition atorvastatin calcium and aspirin were eluted at 
the 4.7 and 2.2 min respectively. The concentration of 
atorvastatin calcium and aspirin estimation in the capsule 
was found to be in the range 99.33-101.43 % and 99.71-
101.60 %.48 Determination of atorvastatin and its impurities 
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in bulk drug and tablet by gradient RP-HPLC assay with UV 
detection was carried out by Erturk et al. (2003). Best 
resolution was obtained on a Luna C18 column with 
acetonitrile ammonium acetate buffer pH 4-THF as a mobile 
phase. Samples were eluted with the mobile phase at flow 
rate 1.0 ml/ min. Detected was carried out at 248 nm.49 
2. U.V. Spectroscopic Methods 
Various U.V. spectroscopic methods for simultaneous 
determination of atorvastatin and its combination with 
other drugs have been reported. Among various analytical 
methods for the estimation of atorvastatin U.V. 
spectroscopic methods play an important role in the field of 
analysis and in the quantitative determination. Bernard et al. 
(2018) carried out new spectrophotometric method for the 
estimation of atorvastatin calcium (ATR) and aspirin (ASP) 
using urea as hydrotropic solubilizing agent. The developed 
method used the simultaneous equation method (method-A) 
using 243 nm and 233 nm as absorbance maxima for ATR 
and ASP respectively and Q-absorbance ratio method 
(method-B), which is based on the measurement of 
absorptivity at iso-absorptive point 239 nm and 243 nm 
(absorption maximum of atorvastatin). The calibration 
curves for both drugs were found to be linear in the 
concentration range of 10-50µg/ml. The mean recovery of 
the drugs from the combination tablets was found to be 
98.83 % for atorvastatin and 97.77 % for aspirin for method-
A and 98.09 % and 98.06 % for method-B respectively.50 In 
2018 Tomlesh et al. carried out simultaneous estimation of 
atorvastatin calcium and telmisartan in tablet dosage form 
by spectrophotometry. The absorption maxima at 246 nm 
and 298 nm were used for the estimation of atorvastatin 
calcium and telmisartan respectively. Both the drugs obey 
Beer-Lambert’s law within the range of 01-06 μg/ml for 
atorvastatin calcium and 04-24 μg/ml for telmisartan with a 
correlation coefficient (r2= 0.9998) and (r2= 0.9999) 
respectively. The recovery study was carried out by 
standard addition method. The average percent recovery 
was found to be 99.67 for atorvastatin calcium and 100.20 
for telmisartan. The method was validated according to 
international conference on harmonization (ICH) guidelines 
with respect to linearity, recovery, precision, LOD, and 
LOQ51.  In another study Alshabrawy et al.  (2017) worked 
on sensitive spectrophotometric determination of 
atorvastatin in pharmaceutical formulation by ion pair 
complexation with pararosaniline hydrochloride. In this 
study different factors affecting the formation of the ion pair 
and its stability were studied and optimized in order to 
obtain the best conditions for the experiment. Method 
validation was done over a concentration range of 1 to 8 
µg/ml. The method was proven to be sensitive with limit for 
quantitation of 0.93 µg/ml and limit of detection of 0.31 
µg/ml. The red colored ion pair is easily extractable in 
organic solvent and showed maximum absorption at 547 
nm. 52 Al-Adl et al. (2017) studied spectrophotometric 
determination of atorvastatin calcium and rosuvastatin 
calcium in bulk and dosage form using p-
dimethylaminobenzaldehyde. This method depended on the 
formation of colored chromogen between atorvastatin 
calcium and rosuvastatin calcium and p-
dimethylaminobenzaldehyde (PDMAB) in acidic conditions. 
The reaction mixture exhibited maximum absorbance at λ 
max 540 and 570 nm for atorvastatin calcium and 
rosuvastatin calcium, respectively.  The method was linear 
over the concentration range of 20-160 µg/ml and 2-16 
µg/ml for atorvastatin calcium and rosuvastatin calcium, 
respectively.53 Ramadan et al. (2015) worked on 
determination of atorvastatin calcium in pure and its 
pharmaceutical formulations using iodine in acetonitrile by 
UV-Visible spectrophotometric method. The method was 
based on the oxidation of atorvastatin calcium by iodine and 
formation triiodide (I3−) complex. The formed complex was 
measured at 291 and 360 nm against the reagent blank 
prepared in the same manner. The developed method obeys 
beer’s law within a concentration range of 0.5586-11.173 
μg/ml. The relative standard deviation did not exceed 3.0% 
and regression analysis showed a good correlation 
coefficient (r2= 0.9995). The limit of detection (LOD) and the 
limit of quantification (LOQ) were to be 0.056 and 0.17 
μg/ml, respectively. The developed method can be applied 
for the determination of atorvastatin in pure and its 
commercial tablets without any interference from excipients 
(at λ max =291 & 360 nm), ezetimibe (EZE), fenofibrate 
(FEN) and aspirin (ASP) at λ max =360 nm with average 
recovery of 99.45 to 102.4%.54   Virani et al. (2015) have 
discussed simultaneous estimation of irbesartan and 
atorvastatin by first order derivative spectroscopic method 
in their synthetic mixture. The derivative 
spectrophotometric method was based on the determination 
of both the drugs at their respective zero crossing point 
(ZCP). The first order derivative spectra were obtained in 
methanol and the determinations were made at 225.20 nm 
(ZCP of atorvastatin) for irbesartan and 308.15 nm (ZCP of 
irbesartan) for atorvastatin. The linearity was obtained in 
the concentration range of succinate 5-30 μg/ml for 
irbesartan and 5- 30 μg/ml for atorvastatin succinate. The 
mean recovery was 99.25 and 99.65% for irbesartan and 
atorvastatin succinate, respectively.55 A new simple 
spectroscopic method for estimation of atorvastatin tablets 
using hydrotropic solubilization technique was carried out 
by Rani et al (2015). For the estimation of atorvastatin 
(ATV) in tablet dosage form used 0.5 M sodium benzoate 
aqueous solution as a hydrotropic agent. Atorvastatin (ATV) 
showed maximum absorbance at a wavelength of 268 nm 
and beer’s law was obeyed in the concentration range of 0.1-
0.6 μg/ml. The method was validated according to ICH 
guidelines. 56 Naveed et al. (2014) carried out simple UV 
spectrophotometric assay of atorvastatin API formulation 
and their comparative study. The assay was based on the 
ultraviolet UV absorbance maxima at about 244 nm 
wavelength of atorvastatin using methanol as solvent. A 
sample of drug was dissolved in methanol to produce a 
solution containing atorvastatin. Similarly, a sample of 
ground tablets of different brand were extracted with 
methanol and diluted with the same methanol. The 
absorbance of sample preparation was measured at 244 nm 
against the solvent blank and the assay was determined by 
comparing with the absorbance of available brand.57  Ashour 
et al. (2013) carried out new kinetic spectrophotometric 
method for determination of atorvastatin in pure and 
pharmaceutical dosage forms. The method involved the 
oxidative coupling reaction of atorvastatin (AVS) with 3-
methyl-2-benzothiazolinone hydrazone hydrochloride 
monohydrate (MBTH) in the presence of Ce (IV) in an acidic 
medium to form colored product with λ max at 566 nm. The 
reaction was followed spectrophotometrically by measuring 
the increase in absorbance at 566 nm as a function of time. 
The initial rate and fixed time methods were adopted for 
constructing the calibration curves. The linearity range was 
found to be 2-20 µg/ml for initial rate and fixed time 
methods. The limit of detection for initial rate and fixed time 
methods is 0.093 and 0.064 µg/ml, respectively. Molar 
absorptivity for the method was found to be 3.36×104 
l/molcm.58 Kaliappanlango et al (2012) carried out validated 
spectrophotometric methods for the simultaneous 
determination of telmisartan (TETM) and atorvastatin (ATV) 
in bulk and tablets. The first method was based on first-
order derivative spectroscopy. The sampling wavelengths 
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were 223 nm (zero crossing of TETM) where ATV showed 
considerable absorbance and 272 nm (zero crossing of ATV) 
where TETM showed considerable absorbance. The second 
method Q-analysis (absorbance ratio), involved formation of 
Q-absorbance equation using respective absorptivity values 
at 280.9 nm (isosbestic point) and 296 nm (λ max of TETM). 
The third method involved determination using 
multicomponent mode method; sampling wavelengths 
selected were 296.0 and 246.9 nm. TETM and ATV followed 
linearity in the concentration range of 5-40 and 4-32 μg/ml 
for method I, 5-30 μg/ml and 2-24 μg/ml for method II and 
III, respectively. 59 Spectrophotometric estimation of 
atorvastatin calcium & fenofibrate in tablet dosage form was 
carried out by Hirave et al (2013).  UV spectrophotometric 
method was developed for the estimation of atorvastatin 
calcium & fenofibrate in tablet dosage form by using 
simultaneous equation method. The drug obeyed beer’s law 
& showed good correlation near to 0.999. Absorption 
maxima of atorvastatin calcium & fenofibrate were found to 
be at 246 and 286 nm respectively. Beer’s law was obeyed in 
concentration rang of 1-10 μg/ml for atorvastatin calcium & 
2-20 μg/ml for fenofibrate. The method has been validated 
for linearity, accuracy & precision. The recovery was more 
than 99%.60 In another study estimation of aspirin and 
atorvastatin calcium in combined dosage form by 
spectrophotometric method was carried out by Patel et al. 
(2010). Methanol was used as a solvent in this study. During 
analysis second order derivative spectroscopy method was 
used to eliminate spectral interference, with 266.78 nm and 
237.35 nm as zero crossing points for aspirin and 
atorvastatin calcium respectively.61 Simultaneous 
spectrophotometric estimation of atorvastatin calcium and 
amlodipine besylate in combined tablet dosage form by area 
under curve method was carried out by Jani et al (2010). In 
this study methanol was used as a solvent. The proposed 
area under curve method involved the measurement of area 
at selected analytical wavelength ranges and performing the 
analysis using “Cramer’s Rule” and “Matrix Method”. Two 
analytical wavelength ranges selected were 256-238.5 nm 
and 368-352 nm for the estimation of ATR (atorvastatin) 
and AML (amlodipine). The linearity of the proposed method 
was investigated in the range of 5-50 µg/ml (r2 = 0.9998) for 
ATR and 5-50 µg/mL (r2= 0.9997) for AML, respectively. The 
percentage mean recovery was found to be 99.83% for ATR 
and 99.60% for AML. The method was statistically validated 
for its linearity, accuracy and precision. Both inter-day and 
intra-day variation was found to be showing less % RSD 
value indicating high grade of precision of the method.62 In 
2011 Kumbhar et al. carried out development and validation 
of derivative spectrophotometric method for estimation of 
atorvastatin calcium (AT) and amlodipine besylate (AM) in 
tablet dosage form.   The AT and AM stock solutions were 
prepared in (50:50 V/V) methanol: water. The method of 
analysis was derivative spectroscopy to eliminate spectral 
interference by measuring absorbances at 241nm and 250 
nm for AM and AT respectively.  The AT and AM were linear 
in concentration range of 0-14 µg/ml and 0-7 µg/ml 
respectively. The limit of detection (LOD) and limit of 
quantitation (LOQ) of AM was 0.29 and 0.75 µg respectively. 
The limit of detection (LOD) and limit of quantitation (LOQ) 
of AT was 0.21 and 0.60 µg.63 Simultaneous spectroscopic 
estimation of atorvastatin calcium and aspirin in 
pharmaceutical dosage form was successfully carried out by 
Patel et al. (2012). In this study method-1 simultaneous 
equations and method-2 Q-absorbance ratio method was 
used. λ max was found 240 nm and 230 nm for atorvastatin 
calcium and aspirin respectively and 290.5 nm 
(isoabsorptive point). A 0.1N NaOH was used as solvent. 
Linearity was observed in the concentration range of 2-26 
µg/ml for atorvastatin calcium and 5-25 µg/ml for aspirin 
respectively.64 Havele et al. (2011) carried out simultaneous 
determination of atorvastatin calcium and pioglitazone 
hydrochloride in its multicomponent dosage forms by UV 
spectrophotometry. A simple, accurate and precise 
spectrophotometric method was developed for 
simultaneous estimation of atorvastatin & pioglitazone in 
bulk and tablet showed maximum absorbance at 210 nm for 
atorvastatin while showed maximum absorbance for 
pioglitazone at 225 nm. The overlain spectra showed 
maximum absorbance at 242 nm.65 Spectrophotometry and 
liquid chromatography methods for estimation of 
atorvastatin calcium and fenofibrate in tablets was reported 
by Nakarani et al. (2007). Two simple and accurate methods 
to determine atorvastatin calcium (ATO) and fenofibrate 
(FEN) in combined dosage forms were developed using 
second-derivative spectrophotometry and reversed-phase 
liquid chromatography (LC). ATO and FEN in combined 
preparations (tablets) were quantitated using the second-
derivative responses at 245.64 nm for ATO and 289.56 nm 
for FEN in spectra of their solution in methanol. The 
calibration curves showed linearity [ (r2) = 0.9992 for ATO 
and 0.9995 for FEN] in the concentration range of 3-15 
μg/ml for ATO and FEN. In the LC method, analysis was 
performed on a Hypersil ODS-C18 column (250 mm x 4.6 
mm id, 5μ particle size) in the isocratic mode using the 
mobile phase methanol-water (90: 10, v/v), adjusted to pH 
5.5 with orthophosphoric acid, at a flow rate of 1 ml/min.66 A 
simple UV-spectrophotometric method for simultaneous 
estimation of telmisartan and atorvastatin calcium in bulk 
and tablet dosage form was carried out by Chaudhari et al 
(2010). In this study an UV spectrophotometric method 
using simultaneous equation was developed for the 
simultaneous determination of telmisartan and atorvastatin 
calcium in a binary mixture. In the proposed method, the 
signals were measured at 296.0 nm and 247.0 nm 
corresponding to absorbance maxima of telmisartan and 
atorvastatin calcium in methanol respectively. Linearity 
range was observed in the concentration range of 5-30 
µg/ml for both the drugs. Concentration of each drug was 
obtained by using the absorptivity values calculated for both 
drugs at two wavelengths, 296.0 nm and 247.0 nm and 
solving the simultaneous equation.67  In 2010 Vijayalakshmi 
et al. carried out simultaneous UV spectrophotometric 
determination of atorvastatin calcium and telmisartan in 
tablet dosage form. Two accurate, precise, sensitive and 
economical procedures for simultaneous estimation of 
atorvastatin calcium and telmisartan in tablet dosage forms 
have been developed.  In this study first method employed 
formation and solving of simultaneous equations using 219 
nm and 257nm as two analytical wavelengths for both drugs 
in 0.1 N NaOH. The second method was Q- analysis based on 
measurement of absorptivity at 240 nm (as isobestic point) 
and 257nm (λ max of ATV). Atorvastatin calcium and 
telmisartan at their respective λ max 257 nm and 219 nm 
and at 240 (isosbestic point) showed linearity in a 
concentration range of 50-150 µg/ml and 10-50 µg/ml 
respectively.68 Spectroscopic study for estimation of 
atorvastatin calcium in tablet dosage form was reported by 
Prajapati et al (2011). Standard stock solution was prepared 
in methanol and λ max was found 246nm. The proposed 
method obeys beer’s law in the range of 5-25 µg/ml. 
Absorption maxima was determined with 10 µg/ml by 
scanning in the range of 200-400 nm. % Recovery studies 
was found in the range of 99.96%-100.03%.69 In another UV 
spectrophotometric study the simultaneous estimation of 
atorvastatin calcium and pioglitazone hydrochloride was 
carried out by Sasikala et al (2013). Atorvastatin calcium 
and pioglitazone hydrochloride obeyed beer’s law in 
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concentration ranges of 2-16 μg/ml with correlation 
coefficient of 0.9992 for atorvastatin calcium and correlation 
coefficient of 0.9967 for pioglitazone hydrochloride 
respectively. The zero-crossing point for atorvastatin 
calcium and pioglitazone hydrochloride was found 226 and 
278 nm respectively in water. The LOD values were found to 
be 0.594 μg/ml and 0.105 μg/ml for atorvastatin calcium 
and pioglitazone hydrochloride respectively. The LOQ values 
were found to be 1.800 μg/ml and 0.318 μg/ml for 
atorvastatin calcium and pioglitazone hydrochloride 
respectively. The % RSD for intraday and interday precision 
were found to be less than 2 %. Recovery by this method 
was found to be 98 % - 101 % for both the analytes.70  Jadhav 
et al (2014) carried out dual wavelength spectrophotometric 
method for simultaneous estimation of atorvastatin calcium 
and felodipine from tablet dosage form. The calibration 
curves determination for both drugs has been carried out in 
0.1 N HCl, phosphate buffer pH 6.8, and acetonitrile (ACN)-
water (70: 30 V/V). Linearity range was observed in the 
concentration range of 2 to 12 µg/ml for felodipine (FEL) 
and 20 to 100 µg/ml for atorvastatin (ATR). Percent 
concentration estimated for ATR and FEL was 100.12 ± 1.03 
and 99.98 ± 0.98, respectively.71 In 2014 Ibrahim et al. 
reported simultaneous determination of amlodipine 
besylate and atorvastatin calcium by using 
spectrophotometric method with multivariate calibration 
and hplc method. The method was based on the 
spectrophotometric measurements of the drugs in the range 
of 200-400 nm together with multivariate calibration 
methods. Resolution of the binary mixture under 
investigation has been accomplished mainly by using partial 
least squares (PLS) and principal component regression 
(PCR). The RP-HPLC method utilized a YMC-pack pro C18 
ODS-A (25 cm x 4.6 mm, 5 µm) column, at room 
temperature, optimum mobile phase consisted of methanol 
and 0.01 M sodium dihydrogen phosphate buffer (75:25, 
v/v), pH adjusted to 3.5 with orthophosphoric acid solution. 
The flow rate was monitored at 1.2 ml/min, and UV 
detection at 239 nm.72 Spectrophotometric estimation of 
atorvastatin calcium in tablet dosage forms was carried out 
by Jadhav et al. (2010). This method utilized 2.0 M urea 
solution as, hydrotropic solubilizing agent. In the urea 
solution atorvastatin calcium showed maximum absorbance 
at 240 nm. The 2.0 M urea solution did not show any 
interference with the sampling wavelength. Another method 
was formation of green color complex between the drug 
atorvastatin calcium and 0.3 % w/v ferric chloride and 0.02 
% w/v potassium ferricyanide. The green colored complex 
showed the maximum absorbance at 787 nm. The 
hydrotropic agent and additives used in the manufacture of 
tablets did not interfere in the analysis. The results of tablet 
analysis were found be in range of 99.26 to 100.12%   with 
standard error values of 0.2728 and 0.2082 by hydrotropy 
and colorimetry respectively. The results of analysis of both 
methods were validated statistically following ICH Q2A (R1) 
guidelines. Both methods were found to be useful for 
accurate, sensitive, selective, precise and robust analysis of 
atorvastatin from marketed formulations.73 Patil et al. 
(2009) reported simultaneous determination of atorvastatin 
calcium and telmisartan in tablet dosage form by 
spectrophotometry. In this study three accurate, precise, 
sensitive and economical procedures for simultaneous 
estimation of atorvastatin calcium and telmisartan in tablet 
dosage form have been developed. The methods employed 
were absorbance correction method (I), first order 
derivative spectroscopic method (II) and duel wavelength 
method (III). The first method employed wavelength 328 nm 
for direct estimation of telmisartan where atorvastatin 
calcium shows nil absorbance. Estimation of atorvastatin 
calcium was carried out after correction for absorbance of 
telmisartan at 241 nm. The second method was based on 
first order derivative spectroscopy. Wavelengths 297 nm 
and 241.8 nm were selected for the estimation of the 
atorvastatin calcium and telmisartan, respectively. In the 
third method, atorvastatin calcium was determined by 
plotting the difference in absorbance at 258 and 291 nm 
(difference is zero for telmisartan) against the concentration 
of atorvastatin calcium. Similarly, for the determination of 
telmisartan, the difference in absorbance at 225 and 252 nm 
(difference is zero for atorvastatin calcium) was plotted 
against the concentration of telmisartan. Both the drugs 
obey beer’s law in the concentration range 5-30 μg/ml.74 
Simultaneous estimation of atorvastatin calcium and 
amlodipine besylate in tablet dosage forms by 
spectrophotometric method was proposed by Chaudhari et 
al (2010). The method was based on property of additivity of 
absorbances. The two wavelengths on amlodipine besylate 
curve were found out where it showed same absorbance, 
which were 257.4 and 360.0 nm. At 360.0 nm, amlodipine 
besylate showed some absorbance while atorvastatin 
calcium showed zero absorbance. Both the drugs gave 
absorbance at 257.4 nm. The method involved solving of an 
equation based on measurement of absorbances at two 
wavelengths 257.4 and 360.0 nm.75 Bernard et al (2013) 
studied simultaneous estimation of atorvastatin calcium and 
amlodipine besylate by UV spectrophotometric method 
using hydrotropic solubilization. The developed method 
used the absorption ratio or Q‐value which was based on the 
measurement of absorptivity at 293 nm (iso-absorptive 
point, both the drugs were found to have same absorbance 
at this wave length) and 247 nm (absorption maximum of 
one of the drugs, atorvastatin). Both the drugs were 
insoluble in water and require corrosive organic solvents for 
solubilization. Therefore, used 2M urea by hydrotropic 
solubilization method. The calibration curves for both drugs 
were found to be linear in a concentration range of 10-
60µg/ml. No significant interference was observed from the 
tablet excipients and 2M urea used for solubilization. The 
mean recovery of the drugs from the combination tablets 
was 100.65% for atorvastatin and 101.42% for amlodipine 
respectively. 76 
3. Other Analytical Method  
UPLC-MS/MS method was developed by Rezk et al. (2018) 
for quantification of amlodipine and atorvastatin in human 
plasma. In this study eplerenone was used as an internal 
standard (IS). Multiple-reaction monitoring in positive 
electrospray ionization mode was utilized in Xevo TQD LC-
MS/MS. Double extraction was used in sample preparation 
using diethyl ether and ethyl acetate. The prepared samples 
were analyzed using an Acquity UPLC BEH C18 (50 cm 
× 2.1 mm, 1.7 μm) column. Ammonium formate and 
acetonitrile, pumped isocraticaly at a flow rate of 
0.25 ml/min. Method validation was done as per the US Food 
and Drug Administration guidelines. Linearity was achieved 
in the range of 0.1-10 ng/ml for amlodipine (AML) and 0.05-
50 ng/ml for atorvastatin (ATO). Intra-day and inter-day 
accuracy and precision were calculated and found to be 
within the acceptable range.77 Simultaneous determination 
of acetylsalicylic acid, hydrochlorothiazide, enalapril and 
atorvastatin in a polypill-based quaternary mixture by TLC 
was carried out by Maslanka et al. (2018). Chromatographic 
separation was performed using TLC silica gel 60 plates with 
fluorescent indicator F254 as the stationary phase and a 
mixture of n-hexane–ethyl acetate–methanol–water–acetic 
acid (8.4 + 8 + 3 + 0.4 + 0.2, v/v/v/v/v) as the mobile phase. 
Densitometric measurements were carried out at λ max= 
210 nm when determining enalapril (ENA) and at λ max = 
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265 nm in the case of the other drugs. Peaks of examined 
substances were well separated in the recorded 
chromatograms, enabling the evaluation of the results in 
terms of both qualitative and quantitative analysis. The 
method was specific for the analyzed components and was 
characterized by high sensitivity. The LOD was between 
0.043 and 0.331 μg/spot, and LOQ was between 0.100 and 
0.942 μg/spot. Recovery was in the range of 97.02–101.34%. 
The linearity range was broad and ranged from 0.600 to 6.0 
μg/spot for acetylsalicylic acid, from 0.058 to 1.102 μg/spot 
for hydrochlorothiazide, from 0.505 to 6.56 μg/spot for 
enalapril, and from 0.100 to 1.000 μg/spot for atorvastatin. 
The method was characterized by good precision, with RSD 
values that ranged from 0.10 to 2.26%.78 Szentmiklosi et al. 
(2017) reported micellar electro kinetic capillary 
chromatography method for simultaneous determination of 
atorvastatin and ezetimibe in combined pharmaceutical 
products. The best results were obtained when using fused 
silica capillary (48 cm length X 50 µm ID) and 25 mM borate 
buffer electrolyte at pH 9.3 containing 25 mM sodium 
dodecyl sulfate (SDS), + 30 kV applied voltage, 20 ºC system 
temperature. The separation was achieved in approximately 
2 minutes, with a resolution of 7.02, the order of migration 
being atorvastatin followed by ezetimibe.79 Liquid 
chromatography–mass spectrometry (LC–MS) method for 
estimation of amlodipine and atorvastatin in human plasma 
was carried out by Danafar et al (2016). Analytes were 
extracted from plasma by simple liquid–liquid extraction 
technique using ethyl acetate. The reconstituted samples 
were chromatographed on C18 column by pumping 
acetonitrile–water (10 mM CH3COONH4, pH 3.0) = 70:30 
(v/v) at a flow rate of 0.15 ml/min. The standard curves 
were assigned to be linear in the range of 0.2–20 ng/ml for 
atorvastatin and 0.1–10 ng/ml for amlodipine with mean 
correlation coefficient of ≥0.999 for each analyte. The intra-
day and inter-day precision and accuracy results were well 
within the acceptable limits.80 In 2015 Yang et al. reported 
high‐throughput salting‐out‐assisted liquid–liquid extraction 
for the simultaneous determination of atorvastatin, 
ortho‐hydroxy atorvastatin, and para‐hydroxy atorvastatin 
in human plasma using ultrafast liquid chromatography with 
tandem mass spectrometry. A high‐throughput, specific, and 
rapid liquid chromatography with tandem mass 
spectrometry method was established and validated for the 
simultaneous determination of atorvastatin and its two 
major metabolites, ortho‐hydroxy atorvastatin and 
para‐hydroxy atorvastatin, in human plasma. 
Chromatographic separation was performed on a Kinetex XB 
C18 column utilizing a gradient elution starting with a 60% 
of water solution (1% formic acid), followed by increasing 
percentages of acetonitrile. Analytes were detected on a 
tandem mass spectrometer equipped with an electrospray 
ionization source that was operated in the positive mode, 
using the transitions of m/z 559.3 → m/z 440.2 for 
atorvastatin, and m/z 575.3 → m/z 440.2 for both ortho‐ and 
para‐hydroxy atorvastatin. Deuterium‐labeled compounds 
were used as the internal standards. The method was 
validated over the concentration ranges of 0.0200–15.0 
ng/ml for atorvastatin and ortho‐hydroxy atorvastatin, and 
0.0100–2.00 ng/ml for para‐hydroxy atorvastatin with 
acceptable accuracy and precision.81 In another study, Gligor 
et al (2015) discussed direct and simultaneous 
quantification of atorvastatin and amlodipine in tablets by 
NIR Spectroscopy. Near infrared spectroscopy (NIRS) is a 
technique widely used for direct and non-destructive 
analysis of solid samples.  In this study NIRS method for the 
simultaneous quantification of atorvastatin and amlodipine 
in fixed-dose combination tablets was developed and fully 
validated. The partial least squares (PLS) calibration model 
was developed based on the 26 samples prepared according 
to a D-optimal experimental design with 2 factors and 5 
levels. The best predictive model for atorvastatin was 
developed using standard normal variate pre-processing 
method, 7 PLS factors; the best predictive model for 
amlodipine was developed using first derivate followed by 
standard normal variate pre-processing method and 7 PLS 
factors. The method was validated in terms of linearity, 
trueness, precision and accuracy. Furthermore, comparative 
data obtained on independent samples showed no statistical 
difference (p>0.05) between the results predicted by the 
NIRS method and the values obtained using HPLC reference 
method.82 LC-ESI-MS/MS method for simultaneous 
estimation of atorvastatin and its active metabolites in 
human plasma was carried out by Jadhav et al (2014). The 
aim of the proposed research work was to develop and 
validate a simple, selective and sensitive method for the 
analysis of atorvastatin (ATR), ortho-hydroxy atorvastatin 
(o-HATR) and para- hydroxy atorvastatin (o-HATR) in 
human plasma using liquid chromatography-tandem mass 
spectrometry (LC-ESI-MS/MS). All three analytes and 
corresponding deuterium (d5)-labeled internal standards 
were extracted from 500 μl of human plasma by liquid-liquid 
extraction (LLE) technique. An isocratic mode is used to well 
separate analytes and interference peaks using a 
CHIRALPAK IC-3 (150 x 4.6 mm, 3 µm) column using a 
mobile phase consisting of acetonitrile: 0.1% acetic acid 
(50:50, v/v). The m/z of ATR, o- HATR and p-HATR are 
559.20/440.00, 575.30/440.20 and 575.30/440.00 
respectively. Mass spectrometry detection was carried out in 
positive electrospray ionization mode, with multiple-
reaction monitoring scan. Linearity ranges are 0.5 to 160 
ng/ml for ATR, 0.5 to 50 ng/ml o-HATR and 0.2 to 10 ng/ml 
p-HATR respectively.83 Ramadan et al (2014) carried out 
TLC for simultaneous determination of amlodipine (AMD), 
atorvastatin (AT), rosuvastatin (RSV) and valsartan (VAL) in 
pure form and in tablets using phenyl-modified aleppo 
bentonite.  Study was carried out using acetonitrile: buffer 
(0.025M of NaH2PO4.2H2O in water) 45:55, v/v as mobile 
phase having pH 6.0. The particles of Aleppo Bentonite 
which have diameter less than 45 µm were treated by 
concentrated hydrochloric acid (BA), after that grafted 
firstly by dimethyldichlorosilane, then secondly by grignard 
reagent (phenyl magnesium bromide). The surface 
properties of phenyl-modified bentonite were studied by 
nitrogen adsorption at 77K. The retardation factors (Rf) of 
AMD, AT, RSV and VAL were 0.27, 0.41, 0.62 and 0.78, 
respectively. Linearity for determination of AMD, AT, RSV 
and VAL was in the range 0.50-10.00 for AMD and 1.00-
20.00 μg/spot AT, RSV and VAL. The minimum determined 
concentration was 0.5 μg/spot for AMD and 1.0 μg/spot for 
AT, RSV and VAL with percent relative standard deviation 
(RSD%) 4.0%, 3.8%, 3.2% and 4.2%, respectively. The limits 
of detection (LOD) and the limits of quantification (LOQ) 
were found to be 0.063 and 0.19, 0.125 and 0.38, 0.106 and 
0.32, 0.142 and 0.43 µg/spot for AMD, AT, RSV and VAL, 
respectively.84 Baghdady (2013) reported spectrophoto-
metric and TLC-densitometric methods for the simultaneous 
determination of ezetimibe and atorvastatin calcium. Three 
sensitive methods were developed for simultaneous 
determination of ezetimibe (EZB) and atorvastatin calcium 
(ATVC) in binary mixtures. First derivative (D1) 
spectrophotometry was employed for simultaneous 
determination of EZB (223.8 nm) and ATVC (233.0 nm) with 
a mean percentage recovery of 100.23 ± 1.62 and 99.58 ± 
0.84, respectively. Linearity ranges were 10.00-30.00 µg/ml 
and 10.00-35.00 µg/ml, respectively. Isosbestic point (IS) 
spectrophotometry, in conjunction with second derivative 
(D2) spectrophotometry was employed for analysis of the 
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same mixture. Total concentration was determined at IS, 
224.6 nm and 238.6 nm over a concentration range of 
10.00–35.00 µg/ml and 5.00–30.00 µg/ml, respectively. 
ATVC concentration was determined using D2 at 313.0 nm 
(10.00–35.00 lg/ml) with a mean recovery percentage of 
99.72 ± 1.36, while EZB was determined mathematically at 
224.6 nm (99.75 ± 1.43).85 Gajula et al. (2012) worked on 
simultaneous determination of atorvastatin and aspirin in 
human plasma by LC–MS/MS: Its Pharmacokinetic. The 
analytes were extracted from human plasma by the liquid–
liquid extraction technique using methyl tert-butyl ether. 
The reconstituted samples were chromatographed on a 
Zorbax XDB Phenyl column by using a mixture of 0.2% acetic 
acid buffer, methanol, and acetonitrile (20:16:64, v/v/v) as 
the mobile phase at a flow rate of 0.8 ml/min. Proguanil and 
furosemide were used as the internal standards for the 
quantification of atorvastatin and aspirin, respectively. Prior 
to detection, atorvastatin and aspirin were ionized using an 
ESI source in the multiple reaction monitoring (MRM) mode. 
The ions were monitored at the positive m/z 559.2→440.0 
transition for atorvastatin and the negative m/z 
179.0→136.6 transition for aspirin. The calibration curve 
obtained was linear (r2 ≥ 0.99) over the concentration range 
of 0.20–151 ng/ml for atorvastatin and 15.0–3000 ng/ml for 
aspirin. A run time of 3.0 min for each sample made it 
possible to analyze more than 300 human plasma samples 
per day.86 Simultaneous determination of atorvastatin, 
aspirin, and their degradation products in capsules with 
ultra HPLC was carried out by Vora et al. (2008). Separation 
was achieved on acquity UPLC TM BEH C18 column (2.1 × 50 
mm, 1.7 μm). The mobile phase used was a mixture of 
acetonitrile and phosphate buffer (0.01 M, pH 2.0) and 
separation was achieved with flow rate 0.6 ml/min. 
Quantification was carried out on UV detector at 247 nm.87 
In 2008 Kadav et al. reported stability indicating UPLC 
method for simultaneous determination of atorvastatin, 
fenofibrate and their degradation products in tablets. The 
chromatographic separation was performed on acquity 
UPLC BEH C18 column (100 × 2.1 mm, 1.7 µm) using 
gradient elution of acetonitrile and ammonium acetate 
buffer (0.01 M, pH 4.7) at flow rate of 0.5 ml/min. UV 
detection was performed at 247 nm. Total run time was 3 
min within which main compounds and six other known and 
major unknown impurities were separated.88 HPTLC 
determination of atorvastatin in plasma was reported by 
Jamshidi et al. (2007). In this study, 2-step isocratic 
chromatography on silica gel 60F254 HPTLC layer and 
densitometric quantitation at λ = 280 nm was developed for 
the separation of atorvastatin from plasma constituencies 
and sodium diclofenac as peak tracer. The established 
HPTLC method was validated in terms of LOD/LOQ, 
linearity, recovery, and repeatability. The calibration 
function of the analyte was linear in the range 101-353.5 
ng/zone and the correlation coefficient was 0.9969. The 
limits of detection and quantitation were 30.3 and 101 
ng/zone. The recovery and relative standard deviation 
obtained from between-days analysis were 97.5-103.0 and 
1.7-3.4%.89 In another study, Chaudhri et al. (2006) reported 
HPTLC method for the simultaneous estimation of 
atorvastatin calcium and ezetimibe. The stationary phase 
used was precoated silica gel 60F254. The mobile phase 
used was a mixture of chloroform: benzene: methanol: acetic 
acid (6.0:3.0:1.0:0.1, v/v/v/v). The detection of spots was 
carried out at 250 nm. The method was validated in terms of 
linearity, accuracy, precision, and specificity. The calibration 
curve was found to be linear between 0.8 and 4.0 μg/spot for 
atorvastatin calcium and 0.1 and 1.0 μg/spot for ezetimibe. 
The proposed method can be successfully used for the 
determination of drug content of marketed formulation.  90 
Later Yadav et al (2005) gave a simple and sensitive HPTLC 
method for the determination of content uniformity of 
atorvastatin calcium tablets. Precoated silica gel 60 F254 
was used as stationary phase. The mobile phase used was a 
mixture of benzene: methanol, (7:3 v/v). Combination of 
benzene: methanol offered optimum migration (RF = 0.46 ± 
0.02).  Detection of the spots was carried out at 281 nm. The 
method was validated in terms of linearity (200-600 
ng/spots), precision (intra-day variation: 0.25 to 1.01%, 
interday variation: 0.21 to 0.88%), accuracy (99.2 ± 0.48) 
and specificity. The proposed HPTLC method can analyze ten 
or a formulation unit simultaneously on a single plate and 
provided a faster and cost-effective quality control tool for 
routine analysis of atorvastatin calcium tablet formulation. 91 
Farahani et al (2009) carried out quantitation of atorvastatin 
in human plasma using directly suspended acceptor droplet 
in liquid-liquid-liquid microextraction and high-
performance liquid chromatography-ultraviolet detection. 
The methodology was based on liquid-liquid-liquid 
microextraction (LLLME) followed by high-performance 
liquid chromatography-ultraviolet detection (HPLC-UV). 
Atorvastatin (AT) was first extracted from 4.5 ml acidic 
aqueous sample (diluted plasma, donor phase, pH 1) at 
temperature 45 ° C through 400 μl octanol for 4.5 min, while 
being agitated by a stirring bar at 1250 rpm. Then, a 5.5 μl 
free suspended basic aqueous droplet (acceptor phase, pH 
10) was delivered to the top-center position of the organic 
membrane. The mixture was stirred at 650 rpm for 7.5 min 
and the analyte was back-extracted into the droplet. Finally, 
the acceptor phase was taken into a micro syringe and 
injected directly into the HPLC. An enrichment factor of 187 
along with substantial sample clean-up was obtained under 
the optimized conditions. The calibration curve showed 
linearity in the range of 1-500 ng/ml with regression 
coefficient corresponding to 0.996. Limits of detection and 
quantification were 0.4 and 1 ng/ml, respectively. A 
reasonable relative recovery (91%) and satisfactory intra-
assay (4.4-7.0%, n=6) and inter-assay (4.9-7.7%, n=8) 
precision was found during analytical procedure.92 Ashour 
et al. (2011) carried out a novel use of oxidative coupling 
reactions for determination of some statins (cholesterol-
lowering drugs) in pharmaceutical formulations. All 
methods involved the oxidative coupling reaction of 
Atorvastatin (AVS), Fluvastatin (FVS) and Pravastatin (PVS) 
with 3-methyl-2-benzothiazolinone hydrazone 
hydrochloride monohydrate (MBTH) in the presence of Ce 
(IV) in an acidic medium to form colored products with 
λ(max) at 566, 615 and 664 nm, respectively. Beer's law was 
obeyed in the ranges of 2.0-20.0, 4.9-35.4 and 7.0-30.0 μg 
/ml for AVS-MBTH, FVS-MBTH and PVS-MBTH, respectively. 
Molar absorptivities for the above three methods were 
found to be 3.24×10(4), 1.05×10(4) and 0.68×10(4) l/mol/ 
cm respectively.93 Al-Shehri et al. (2012) proposed an 
alternative capillary electrophoresis method for 
simultaneous determination of ezetimibe and atorvastatin in 
pharmaceutical formulations. Separation of both ezetimibe 
and atorvastatin was achieved utilizing fused silica capillary 
(58 cm × 75 μm ID) and background electrolyte solution that 
consisted of phosphate buffer (2.5 mM, pH 6.7): methanol 
(70:30 v/v). The method showed linearity over the range 
2.5-50 μg/ml for ezetimibe (r2 = 0.9992) and 1-100 μg/ml 
for atorvastatin (r2= 0.9999). Within-day and between-day 
RSD for ezetimibe and atorvastatin were found ⩽5.6% and 
⩽2.9%, respectively. The detection limit was found 
0.07 μg/ml for ezetimibe and 0.06 μg/ml for atorvastatin. 
The percentage recoveries of the two drugs from their 
tablets were 99.80 ± 1.76 and 100.19 ± 1.83, respectively.94 
Ali (2018) carried out high sensitivity determination of 
atorvastatin calcium in pharmaceuticals and biological fluids 
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using adsorptive anodic stripping voltammetry onto surface 
of ultra-trace graphite electrode. The developed adsorptive 
anodic stripping voltammetric method was applied for the 
determination of atorvastatin (ATOR) using phosphate 
buffer at pH 3. The low value of LOD and LOQ confirmed the 
sensitivity of the adsorptive anodic stripping voltammetric 
method.95 LC–MS/MS study for determination of 
atorvastatin and aspirin in human plasma was carried out by 
Gajula et al. (2012). The analytes were extracted from 
human plasma by the liquid–liquid extraction technique 
using methyl tert-butyl ether. The reconstituted samples 
were chromatographed on a Zorbax XDB Phenyl column by 
using a mixture of 0.2% acetic acid buffer, methanol, and 
acetonitrile (20:16:64, v/v) as the mobile phase at a flow 
rate of 0.8 ml/min. Prior to detection, atorvastatin and 
aspirin were ionized using an ESI source in the multiple 
reaction monitoring (MRM) mode. The ions were monitored 
at the positive m/z 559.2→440.0 transition for atorvastatin 
and the negative m/z 179.0→136.6 transition for aspirin. 
The calibration curve obtained was linear (r2 ≥ 0.99) over 
the concentration range of 0.20–151 ng/ml for atorvastatin 
and 15.0–3000 ng/ml for aspirin.96 Soni et al. (2014) carried 
out simultaneous determination of atorvastatin calcium and 
olmesartan medoxomil in a pharmaceutical formulation by 
reversed phase high-performance liquid chromatography, 
high-performance thin-layer chromatography (HPTLC), and 
UV spectrophotometric methods. The RP-HPLC separation 
was achieved on a Kromasil C18 column (250 x 4.6 mm, 5-
micron particle size) using 0.01 M potassium dihydrogen o-
phosphate (pH 4 adjusted with o-phosphoric acid)-
acetonitrile (50: 50, v/v) as the mobile phase at a flow rate 
of 1.5 ml/min. Quantification was achieved by UV detection 
at 276 nm. The HPTLC separation was achieved on 
precoated silica gel 60F254 plates using chloroform-
methanol-acetonitrile (4 + 2+ 4, v/v/v) mobile phase. 
Quantification was achieved with UV detection at 276 nm. 
The UV-Vis spectrophotometric method was based on the 
simultaneous equation method that involved measurement 
of absorbance at two wavelengths, i.e., 255 nm (lambda max 
of OLM) and 246.2 nm (lambda max of ATV) in methanol.97 
Simultaneous determination of atorvastatin and ezetimibe in 
human plasma by LC–MS–MS was carried out by El-Bagary 
et al. (2014). In this study pitavastatin was used as an 
internal standard. Liquid–liquid extraction was used for the 
puriﬁcation and preconcentration of analytes from human 
plasma matrix. The chromatographic separation was 
achieved within 3.0 min by an isocratic mobile phase 
consisting of 0.2% formic acid in water-acetonitrile (30:70, 
v/v), ﬂowing through Agilent Eclipse-plus C18, 100 3 4.6 
mm, 3.5 mm analytical column, at a ﬂow rate of 0.6 ml /min. 
Multiple reaction monitoring transitions were measured in 
the positive ion mode for atorvastatin and internal standard, 
while ezetimibe was measured in negative ion mode the 
standard curves were found to be linear in the range of 0.2–
30.0 ng/m1 with a mean correlation coefﬁcient >0.999 for 
both drugs. In human plasma, atorvastatin and ezetimibe 
were stable for at least 36 days at –70 ± 5 °C for 6 h at 
ambient temperature. After extraction from plasma, the 
reconstituted samples of atorvastatin and ezetimibe were 
found stable in an autosampler at ambient temperature for 6 
h.98 Quantification of atorvastatin, o-hydroxyatorvastatin, p-
hydroxyatorvastatin, and atorvastatin lactone in rat plasma 
was studied by Sakac (2016) with LC–MS/MS method. The 
solid-phase extraction was used for preparation of samples. 
Rosuvastatin was chosen as an internal standard. 
Chromatographic separation was achieved on ZORBAX 
Eclipse C18 analytical, 4.6 × 100 mm (3.5 μm) column with a 
gradient mobile phase composed of acetonitrile and 0.1% 
acetic acid, at a flow rate of 400 μl/ min. The column was 
kept at constant temperature (25 °C), and autosampler tray 
temperature was set at 4 °C. The selected reaction 
monitoring (SRM) transitions were selected, (m/z, Q1 → Q3, 
collision energy) atorvastatin (559.47 → 440.03, 22 eV), 
atorvastatin lactone (541.36 → 448.02, 19 eV), ortho-
hydroxy atorvastatin (575.20 → 440.18, 20 eV), para-
hydroxy atorvastatin (575.54 → 440.18, 20 eV), and 
rosuvastatin (482.25 with selected combination of two 
fragments 257.77, 31 eV, and 299.81, 35 eV) in positive ion 
mode. The method was validated over a concentration range 
of 0.5–20 ng/ ml for ortho-hydroxy atorvastatin and para-
hydroxy atorvastatin and 0.1–20 ng /ml for atorvastatin and 
atorvastatin lactone with excellent linearity (r2 ≥ 0.99). The 
detection limits were 0.1 and 0.13 ng/ ml for ortho-hydroxy 
atorvastatin and para-hydroxy atorvastatin, respectively, 
and 0.05 ng /ml for atorvastatin and atorvastatin lactone.99 
Rakibe et al. (2017) carried out UPLC, HR-MS and in-silico 
tools for simultaneous separation, characterization, and in-
silico toxicity prediction of degradation products of 
atorvastatin (AT) and olmesartan (OM).  AT showed labile 
behavior in acidic, basic, neutral, and oxidative stress and 
led to the formation of two degraded products, while OM 
degraded under acidic, basic and neutral and resulted in the 
formation of four degraded products (DPs). All the stressed 
samples of AT and OM were resolved on a C-18 column in 
single run on a gradient liquid chromatographic (LC) mode. 
A complete mass fragmentation pathway of both the drugs 
was established with the help of tandem mass spectrometry 
(MS/MS) studies. Then, the stressed samples were analyzed 
by LC–MS/MS to get the fragmentation patterns of DPs. LC–
MS/MS data helped to propose chemical structure of all the 
DPs. The developed method has shown excellent linearity 
over the range of 10 to 150 μg/ml of OM and AT. The 
correlation coefficient (r2) for OM and AT is 0.999 and 0.998, 
respectively. The main recovery value of OM and AT ranged 
from 99.97% to 100.54%, while the limit of detection (LOD) 
for OM and AT was 0.018 and 0.021 μg/ml, and limit of 
quantitation (LOQ) was found to be 0.051 and 0.063 μg/ml. 
Finally, the in-silico carcinogenicity, mutagenicity, and 
hepatotoxicity predictions of AT, OM, and all the DPs were 
performed by using toxicity prediction software’s, viz., 
TOPKAT, LAZAR, and Discovery Studio ADMET, 
respectively.100 Simultaneous determination of atorvastatin 
and its metabolites in human plasma by UPLC-MS/MS was 
carried out by Liyun et al. (2017). Atorvastatin, its 
metabolites, and the internal standard (IS) were isolated 
from human plasma by liquid–liquid extraction with ethyl 
acetate and then separated on an Acquity UPLC HSS T3 
column (3.0 mm × 100 mm, 1.8 μm) using 0.05% (v/v) 
formic acid in water/acetonitrile (25: 75, v/v) as the mobile 
phase. Atorvastatin and all five metabolites were eluted 
within 4 min. Quantification was performed through positive 
ion electrospray ionization (ESI). The responses of 
atorvastatin and its metabolites ortho-hydroxy atorvastatin, 
para-hydroxy atorvastatin, atorvastatin lactone, ortho-
hydroxy atorvastatin lactone, and para-hydroxy atorvastatin 
lactone were optimized at the m/z 559.4 → 440.1, m/z 575.4 
→ 466.2, m/z 575.5 → 440.5, m/z 541.3 → 448.3, m/z 557.3 
→ 448.3, and m/z 557.3 → 448.3 transitions, respectively. 
The assay was validated in the linear range of 0.2–40 ng/ml 
for atorvastatin and its metabolites. The intra- and inter-day 
precision variations were between 3.3% and 13.9%. The 
matrix effects of plasma were in the range of 102.7–105.5% 
for atorvastatin and 90.3–96.6% for atorvastatin lactone.101 
High performance liquid chromatography (HPLC) and high-
performance thin layer chromatography (HPTLC) estimation 
of atorvastatin calcium and ramipril in capsule dosage forms 
was carried out by Panchal et al. (2010). The HPLC 
separation was achieved on a Phenomenex Luna C18 column 
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(250 x 4.6 mm id, 5 μm) in the isocratic mode using 0.1% 
phosphoric acid-acetonitrile (38: 62, v/v), pH 3.5 +/- 0.05, 
mobile phase at a flow rate of 1 ml/min. The retention times 
were found 6.42 and 2.86 min for atorvastatin calcium and 
ramipril, respectively. Quantification was achieved with a 
photodiode array detector set at 210 nm over the 
concentration range of 0.5-5 μ/ml for each, with mean 
recoveries (at three concentration levels) of 100.06 ± 0.49% 
and 99.95 ±0.63% relative standard deviation (RSD) for 
atorvastatin calcium and ramipril, respectively. The HPTLC 
separation was achieved on silica gel 60 F254 HPTLC plates 
using methanol-benzene-glacial acetic acid (19.6 + 80.0 + 
0.4, v/v/v) as the mobile phase. The Rf values were 0.40 and 
0.20 for atorvastatin calcium and ramipril, respectively. 
Quantification was achieved with UV densitometry at 210 
nm over the concentration range of 50-500 ng/spot for each, 
with mean recoveries (at three concentration levels) of 
99.98 ± 0.75% and 99.87 ± 0.83% RSD for atorvastatin 
calcium and ramipril, respectively. The mean assay 
percentages for atorvastatin calcium and ramipril were 
99.90 and 99.55% for HPLC and 99.91 and 99.47% for 
HPTLC, respectively. 102 
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